🇺🇸 TAZOBACTAM SODIUM in United States

8,603 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 1,632 reports (18.97%)
  2. Drug Ineffective — 1,463 reports (17.01%)
  3. Acute Kidney Injury — 990 reports (11.51%)
  4. Pyrexia — 893 reports (10.38%)
  5. Diarrhoea — 700 reports (8.14%)
  6. Condition Aggravated — 658 reports (7.65%)
  7. Neutropenia — 601 reports (6.99%)
  8. Pneumonia — 577 reports (6.71%)
  9. Thrombocytopenia — 568 reports (6.6%)
  10. Febrile Neutropenia — 521 reports (6.06%)

Source database →

TAZOBACTAM SODIUM in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is TAZOBACTAM SODIUM approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for TAZOBACTAM SODIUM in United States?

Marketing authorisation holder not available in our data.